Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Efficacy and Safety Study of Aplindore in Patients With Early Parkinson Disease

This study has been terminated.
(Neurogen acquired by Ligand Pharmaceuticals - no further support for study. No safety concerns identified.)
Sponsor:
Information provided by:
Neurogen Corporation
ClinicalTrials.gov Identifier:
NCT00809302
First received: December 15, 2008
Last updated: August 27, 2009
Last verified: August 2009
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: October 2009
  Estimated Primary Completion Date: August 2009 (Final data collection date for primary outcome measure)